BR112017008476A8 - Compostos de ácido nucleico para ligação do fator de diferenciação de crescimento 11 - Google Patents

Compostos de ácido nucleico para ligação do fator de diferenciação de crescimento 11

Info

Publication number
BR112017008476A8
BR112017008476A8 BR112017008476A BR112017008476A BR112017008476A8 BR 112017008476 A8 BR112017008476 A8 BR 112017008476A8 BR 112017008476 A BR112017008476 A BR 112017008476A BR 112017008476 A BR112017008476 A BR 112017008476A BR 112017008476 A8 BR112017008476 A8 BR 112017008476A8
Authority
BR
Brazil
Prior art keywords
differentiation factor
nucleic acid
growth differentiation
acid compounds
binding growth
Prior art date
Application number
BR112017008476A
Other languages
English (en)
Other versions
BR112017008476B1 (pt
BR112017008476A2 (pt
Inventor
Ochsner Urs
Green Louis
Zichi Dom
Janjic Nebojsa
Original Assignee
Somalogic Inc
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc, Somalogic Operating Co Inc filed Critical Somalogic Inc
Publication of BR112017008476A2 publication Critical patent/BR112017008476A2/pt
Publication of BR112017008476A8 publication Critical patent/BR112017008476A8/pt
Publication of BR112017008476B1 publication Critical patent/BR112017008476B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Abstract

Aqui descritos são aptâmeros capazes de ligar a proteína do fator de diferenciação de crescimento 11 (GDF11); composições que incluem um aptâmero GDF11 de ligação com uma proteína GDF11; e métodos de fazer e usar o mesmo.
BR112017008476-7A 2014-11-24 2015-11-23 Aptâmero que se liga ao fator de diferenciação de crescimento 11 (gdf11), composição, método de detecção de gdf11 em uma amostra ou de determinar se a amostra compreende gdf11 e kit BR112017008476B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083592P 2014-11-24 2014-11-24
US62/083,592 2014-11-24
US201562113864P 2015-02-09 2015-02-09
US62/113,864 2015-02-09
PCT/US2015/062155 WO2016085860A1 (en) 2014-11-24 2015-11-23 Nucleic acid compounds for binding growth differentiation factor 11

Publications (3)

Publication Number Publication Date
BR112017008476A2 BR112017008476A2 (pt) 2018-01-09
BR112017008476A8 true BR112017008476A8 (pt) 2022-10-18
BR112017008476B1 BR112017008476B1 (pt) 2024-03-12

Family

ID=55069068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008476-7A BR112017008476B1 (pt) 2014-11-24 2015-11-23 Aptâmero que se liga ao fator de diferenciação de crescimento 11 (gdf11), composição, método de detecção de gdf11 em uma amostra ou de determinar se a amostra compreende gdf11 e kit

Country Status (14)

Country Link
US (3) US10808251B2 (pt)
EP (1) EP3224361B1 (pt)
JP (2) JP6768651B2 (pt)
KR (1) KR102558890B1 (pt)
CN (1) CN107075518B (pt)
AU (1) AU2015353767B2 (pt)
BR (1) BR112017008476B1 (pt)
CA (1) CA2966925C (pt)
IL (1) IL251934B (pt)
MX (1) MX2017006521A (pt)
RU (1) RU2708170C2 (pt)
SG (1) SG11201703748PA (pt)
TW (1) TWI695068B (pt)
WO (1) WO2016085860A1 (pt)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5945527A (en) 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
EP2336314A1 (en) 2007-07-17 2011-06-22 Somalogic, Inc. Improved selex and photoselex
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP2606066A1 (en) 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
CA2901394A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
ES2753811T3 (es) * 2012-10-24 2020-04-14 Celgene Corp Biomarcador para uso en el tratamiento de anemia
EP4140497A1 (en) * 2013-04-08 2023-03-01 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
AU2014326975B2 (en) 2013-09-24 2020-05-07 Somalogic Operating Co., Inc. Multiaptamer target detection

Also Published As

Publication number Publication date
IL251934B (en) 2021-07-29
EP3224361B1 (en) 2019-06-19
NZ731836A (en) 2023-11-24
US20230193287A1 (en) 2023-06-22
RU2017121801A (ru) 2018-12-26
JP6858911B2 (ja) 2021-04-14
BR112017008476B1 (pt) 2024-03-12
CN107075518A (zh) 2017-08-18
JP6768651B2 (ja) 2020-10-14
IL251934A0 (en) 2017-06-29
CA2966925C (en) 2023-08-29
EP3224361A1 (en) 2017-10-04
KR102558890B1 (ko) 2023-07-21
RU2017121801A3 (pt) 2019-05-27
WO2016085860A1 (en) 2016-06-02
TW201638335A (zh) 2016-11-01
CN107075518B (zh) 2021-03-09
JP2021000118A (ja) 2021-01-07
MX2017006521A (es) 2017-08-09
JP2017536118A (ja) 2017-12-07
US20190024087A1 (en) 2019-01-24
US10808251B2 (en) 2020-10-20
RU2708170C2 (ru) 2019-12-04
CA2966925A1 (en) 2016-06-02
KR20170084068A (ko) 2017-07-19
BR112017008476A2 (pt) 2018-01-09
AU2015353767B2 (en) 2021-09-09
TWI695068B (zh) 2020-06-01
SG11201703748PA (en) 2017-06-29
US11535852B2 (en) 2022-12-27
AU2015353767A1 (en) 2017-05-25
US20210130829A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
HK1251946A1 (zh) 用於富集核酸群體的組合物和方法
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
ZA202107931B (en) Anti-tau antibodies and methods of use
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PT4023755T (pt) Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
MX2017013878A (es) Amplificación de discordancias optimizadas multiplicadas (moma) - reacción en cadena de polimerasa (pcr) en tiempo real, para evaluar el ácido desoxirribonucleico (adn) libre de celula.
DK3292137T3 (da) Proteiner specifikke for cd137
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
PH12017502277A1 (en) Multi-specific binding proteins
MX2020012893A (es) Formulaciones de proteinas.
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
EP3319930A4 (en) METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
BR112017008476A8 (pt) Compostos de ácido nucleico para ligação do fator de diferenciação de crescimento 11
MY186450A (en) Coumarin-based compounds and related methods
SA516370731B1 (ar) عملية لتحضير جزء وجبة تباع الشمس عالية البروتين
BR112017020329A2 (pt) construto de ácido nucleico para conferir tolerância a herbicida em plantas
EA201591444A1 (ru) Мутированные гены алленоксидсинтазы 2 (aos2)
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/11/2015, OBSERVADAS AS CONDICOES LEGAIS